Jiang Sicong, Wang Xuefeng, Xing Yuxuan, Wu Jiahao, Yuan Xiya
Department of Oncology, Shenzhen Hospital of Guangzhou University of Chinese Medicine Shenzhen 518034, Guangdong, China.
Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva Geneva 1211, Switzerland.
Am J Cancer Res. 2024 Jun 15;14(6):2894-2904. doi: 10.62347/XQHL4852. eCollection 2024.
To explore the value of preoperative prognostic nutritional index (PNI) and controlling nutritional status (CONUT) score in predicting response and prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving programmed cell death protein 1 (PD-1) inhibitors.
A retrospective study was conducted in patients who received PD-1 inhibitors for advanced NSCLC. Patients were assigned by immunotherapy effects into response (partial and complete response, pCR) group (n=52) and non-response (non-pCR) group (n=132). The pathological and clinical data were collected for statistical analysis of factors influencing the immunotherapeutic response. The diagnostic value of PNI and CONUT score for response was assessed. The overall survival (OS) was observed over a 3-year follow-up. COX regression analysis was performed to identify risk factors affecting the survival. The effects of different PNI and CONUT scores on the survival were observed.
Multivariate regression analysis showed that, the tumor-node-metastasis (TNM) stage (P=0.001), PNI (P<0.001), and CONUT score (P<0.001) were associated with response. The non-pCR group had a higher 3-year mortality rate and a shorter 3-year OS than the pCR group (P<0.001). COX regression analysis showed that low PNI and high CONUT score were risk factors for poor prognosis. Further analysis showed that patients with low PNI and high CONUT score had lower 3-year survival rates (P=0.005, P<0.001).
High TNM stage, PNI<50, and CONUT score ≥5 are risk factors for poor response in patients with advanced NSCLC receiving PD-1 inhibitors, and low PNI and high CONUT score suggest poor prognosis.
探讨术前预后营养指数(PNI)和控制营养状况(CONUT)评分在预测晚期非小细胞肺癌(NSCLC)患者接受程序性细胞死亡蛋白1(PD-1)抑制剂治疗的反应及预后中的价值。
对接受PD-1抑制剂治疗的晚期NSCLC患者进行回顾性研究。根据免疫治疗效果将患者分为反应组(部分缓解和完全缓解,pCR)(n = 52)和无反应组(非pCR)(n = 132)。收集病理和临床数据,对影响免疫治疗反应的因素进行统计分析。评估PNI和CONUT评分对反应的诊断价值。在3年随访期内观察总生存期(OS)。进行COX回归分析以确定影响生存的危险因素。观察不同PNI和CONUT评分对生存的影响。
多因素回归分析显示,肿瘤-淋巴结-转移(TNM)分期(P = 0.001)、PNI(P < 0.001)和CONUT评分(P < 0.001)与反应相关。非pCR组的3年死亡率高于pCR组,3年OS短于pCR组(P < 0.001)。COX回归分析显示,低PNI和高CONUT评分是预后不良的危险因素。进一步分析显示,PNI低且CONUT评分高的患者3年生存率较低(P = 0.005,P < 0.001)。
高TNM分期、PNI < 50以及CONUT评分≥5是接受PD-1抑制剂治疗的晚期NSCLC患者反应不佳的危险因素,低PNI和高CONUT评分提示预后不良。